I did not see the original message....and, I was only guessing as to the linkage there between what you posted and what popped up.
Until such time there's more clarity from someone (Bob/other)....I can only "guess" it has something to do (related to) one or more of the Favrille properties.
As you know, (documented) they have a number of property rights (bios) and just guessing they may have stumbled upon something of use (beyond Celgene).
Astaxanthin is used for treating Alzheimer's disease, Parkinson's disease, “brain attack” (stroke), high cholesterol, and an eye condition called age-related macular degeneration (AMD). It is also used for preventing cancer.
How does it work? Astaxanthin is an antioxidant. This effect might protect cells from damage. Astaxanthin might also improve the way the immune system functions. ================================================================== 7/9/12 MMRGlobal Receives First Anti-CD20 Antibody and Online Medical Record Patents in Mexico "Working with legal counsel, consultants, MMR's investment banker B. Riley, and the efforts of management, the Company is exploiting what we own to turn it into revenue for our shareholders and lifesaving technology for cancer patients." http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77310647
11/28/11 MMRGlobal Issued Biotech Patent to Produce B-Cell Vaccines and Treat Cancer Patients MMR announced that it has just been granted a patent protecting methods of making compositions for B-cell vaccines and will soon also have Notice of Allowance for another U.S. Patent protecting "Methods of treating a patient with a B-cell lymphoma." http://ih.advfn.com/p.php?pid=nmona&article=50205520 ------------------------------------------------------------------ The Company is also in the process of forming a separate operating subsidiary to maximize the value of its intellectual property, specifically its biotech assets which the Company believes may have significant commercial value. These assets include its Anti-CD20 antibody which the Company believes to be a first cousin to Rituximab. Rituximab is scheduled to go off patent in 2015 and currently represents over 6.6 billion dollars in annual sales. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=66874119 ------------------------------------------------------------------ 8/18/11 On the biotech side many of you know we have a licensing agreement with Celgene which we have been paid 3 quarters of a million dollars under the terms of that agreement. That agreement is doing exactly what it is supposed to be doing. We have a good working relationship with them and there is no reason to believe at this point that we shouldn’t be able to meet our responsibilities under the terms of that agreement. When we talk about that agreement it is important for everyone to realize that this is a non-exclusive licensing agreement for vaccine related assets in conjunction with a completely separate project Celgene is working on. During the time we have been working with Celgene we have also been able to recover what we believe will turn out to be 1,000’s of human tissue samples, vaccine samples, blood samples, and other antibody samples which on a conservative basis, the first block of 400 samples through resale of commercial market has a value of close to $2M, but when this is combined with the underlying scientific data it is impossible to put a reliable specific number on it because the number goes up so significantly. Since that period of time we have added to that another 1,000 additional samples as a result of a settlement agreement that was reached several weeks ago and it is believed the number could be as much as 2,000 additional samples. There are just so many of them that we have not yet had the chance to actually inventory and catalog what we have. While we were going through those samples we found another collection of insect related research samples which we will receive and have not yet factored in. All of these additional samples are not factored into existing licensing agreements and have just been received so they do all have the opportunity for substantial upside revenue none of which is factored anywhere on our balance sheet. In addition, what makes the biotech an attractive part of the company are the significant tax loss carry forwards that if we can restructure could be worth substantially more than $100M. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=66328770
News 
Market Data 
Discover 
